DRTS
HEALTHCAREAlpha Tau Medical Ltd
$7.59+0.20 (+2.71%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DRTS Today?
No stock-specific AI insight has been generated for DRTS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.57$9.07
$7.59
Fundamentals
Market Cap$668M
P/E Ratio—
EPS$-0.53
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume402K
Avg Volume (10D)—
Shares Outstanding88.0M
DRTS News
20 articles- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona’s Pancreas InstituteYahoo Finance·May 7, 2026
- Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with PembrolizumabYahoo Finance·May 5, 2026
- Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026Yahoo Finance·May 4, 2026
- Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer StudiesYahoo Finance·Apr 27, 2026
- Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)Yahoo Finance·Apr 23, 2026
- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical TrialYahoo Finance·Apr 23, 2026
- Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026Yahoo Finance·Mar 31, 2026
- Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts TeasedMarketbeat·Mar 19, 2026
- Alpha Tau to Present at Sidoti March Virtual Small Cap ConferenceYahoo Finance·Mar 16, 2026
- Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 9, 2026
- Alpha Tau price target raised to $12 from $9 at H.C. WainwrightYahoo Finance·Feb 25, 2026
- HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRTYahoo Finance·Feb 25, 2026
- Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck CancerYahoo Finance·Feb 24, 2026
- Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones AheadYahoo Finance·Jan 29, 2026
- New Strong Sell Stocks for January 27thYahoo Finance·Jan 27, 2026
- DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's EventYahoo Finance·Jan 23, 2026
- New Strong Sell Stocks for January 20thYahoo Finance·Jan 20, 2026
- Peter Melnyk Joins Taiho Oncology as President & Chief Operating OfficerYahoo Finance·Jan 20, 2026
- Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® StudyYahoo Finance·Jan 6, 2026
- Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)Yahoo Finance·Jan 5, 2026
All 20 articles loaded
Price Data
Open$7.38
Previous Close$7.39
Day High$7.61
Day Low$7.30
52 Week High$9.07
52 Week Low$2.57
52-Week Range
$2.57$9.07
$7.59
Fundamentals
Market Cap$668M
P/E Ratio—
EPS$-0.53
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume402K
Avg Volume (10D)—
Shares Outstanding88.0M
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha DaRT) for the treatment of solid cancer in Israel and the United States. The company is headquartered in Jerusalem, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—